Boston Scientific Corporation (FRA:BSX)
88.20
+0.60 (0.68%)
Aug 14, 2025, 5:15 PM CET
Boston Scientific Revenue
Boston Scientific had revenue of $5.06B USD in the quarter ending June 30, 2025, with 22.84% growth. This brings the company's revenue in the last twelve months to $18.49B, up 21.44% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$18.49B
Revenue Growth
+21.44%
P/S Ratio
8.23
Revenue / Employee
$348.94K
Employees
53,000
Market Cap
129.64B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Boston Scientific News
- 5 days ago - Boston Scientific Corporation Is Expensive But Worth It - Seeking Alpha
- 6 days ago - Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue - Benzinga
- 6 days ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 8 days ago - Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions - Business Wire
- 14 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 14 days ago - What's Driving the Market Sentiment Around Boston Scientific? - Benzinga
- 20 days ago - This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate - CNBC
- 22 days ago - Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript - Seeking Alpha